FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 100 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC June 6, 2025 FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... January 8, 2024 Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer June 26, 2019 Νέα διαγνωστική μέθοδος για τον καρκίνο, με τη συμβολή της Microsoft August 5, 2019 Load more HOT NEWS After Saving Thousands of Dogs, Tragedy Strikes Famed Rescue Family Cancer Does Not Affect All People Equally: An Expert Q&A on... Cancer services during COVID-19: 40,000 fewer people starting treatment Immunotherapy approved for some people with advanced melanoma in England
